Proteomic approaches for novel systemic lupus erythematosus (SLE) drug discovery

References

• Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481–490.
   PubMed Web of Science ®Google Scholar
• Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015;11(6):329.
   PubMed Web of Science ®Google Scholar
• Chung SA, Taylor KE, Graham RR, et al. Differential genetic associations for systemic lupus erythematosus based on anti–dsDNA autoantibody production. PLoS Genet. 2011;7(3):e1001323.
   PubMed Web of Science ®Google Scholar
• Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoimmun. 2007;28(1):1–6.
   PubMed Web of Science ®Google Scholar
• Doria A, Tincani A, Lockshin M. Challenges of lupus pregnancies. Rheumatology. 2008;47(suppl_3):iii9–iii12.
   PubMedGoogle Scholar
• Vilas-Boas A, Morais SA, Isenberg DA. Belimumab in systemic lupus erythematosus. RMD Open. 2015;1(1):e000011.
   PubMedGoogle Scholar
• Chan VS-F, Tsang HH-L, Tam RC-Y, et al. B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol. 2013;10(2):133–142.
   PubMed Web of Science ®Google Scholar
• Kamal A, Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev. 2014;13(11):1094–1101.
   PubMed Web of Science ®Google Scholar
• Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol. 2004;172(6):3422–3427.
   PubMed Web of Science ®Google Scholar
• Liu Y, Anders H-J. Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin Pract. 2014;128(3–4):224–231.
   PubMedGoogle Scholar
• Korte EA, Gaffney PM, Powell DW. Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus. Arthritis Res Ther. 2012;14(1):204.
   PubMed Web of Science ®Google Scholar
• Banfi C, Baetta R, Gianazza E, et al. Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins. Drug Discov Today. 2017;22(6):848–869.
   PubMed Web of Science ®Google Scholar
• Zavala-Cerna MG, Martínez-García EA, Torres-Bugarín O, et al. The clinical significance of posttranslational modification of autoantigens. Clin Rev Allergy Immunol. 2014;47(1):73–90.
   PubMed Web of Science ®Google Scholar
• Anderton SM. Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol. 2004 Dec;16(6):753–758.
   PubMed Web of Science ®Google Scholar
• Doyle HA, Mamula MJ. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol. 2012 Feb;24(1):112–118.
   PubMed Web of Science ®Google Scholar
• Schirle M, Bantscheff M, Kuster B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol. 2012;19(1):72–84.
   PubMed Web of Science ®Google Scholar
• Pinna S, Pasella S, Deiana M, et al. Proteomic analysis of human plasma and peripheral blood mononuclear cells in systemic lupus erythematosus patients. J Immunol Methods. 2017;446:37–46.
   PubMed Web of Science ®Google Scholar
• Wu T, Mohan C. Proteomics on the diagnostic horizon: lessons from rheumatology. Am J Med Sci. 2007 Jan;333(1):16–25.
   PubMed Web of Science ®Google Scholar
• Veenstra TD. Proteomic approaches in drug discovery. Drug Discovery Today: Technologies. 2006;3(4):433–440.
   Google Scholar
• Wu T, Mohan C. Proteomic toolbox for autoimmunity research. Autoimmun Rev. 2009 Jun;8(7):595–598.
   PubMed Web of Science ®Google Scholar
• Wu T, Fu Y, Brekken D, et al. Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis. J Immunol. 2010;184(4):2183–2193.
   PubMed Web of Science ®Google Scholar
• Shah D, Mahajan N, Sah S, et al. Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci. 2014;21(1):23.
   PubMedGoogle Scholar
• Gupta R, Yadav A, Misra R, et al. Urinary prostaglandin D synthase as biomarker in lupus nephritis: a longitudinal study. Clin Exp Rheumatol. 2015;33(5):694–698.
   PubMed Web of Science ®Google Scholar
• Pepys M, Butler P. Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun. 1987;148(1):308–313.
   PubMed Web of Science ®Google Scholar
• Bharadwaj D, Mold C, Markham E, et al. Serum amyloid P component binds to Fcγ receptors and opsonizes particles for phagocytosis. J Immunol. 2001;166(11):6735–6741.
   PubMed Web of Science ®Google Scholar
• Connolly KM, Stecher VJ, Rudofsky UH, et al. Elevation of plasma fibronectin and serum amyloid P in autoimmune NZB, BW, and MRL1pr mice. Exp Mol Pathol. 1988;49(3):388–394.
   PubMed Web of Science ®Google Scholar
• Bickerstaff M, Botto M, Hutchinson W, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999;5(6):694.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wu J, Qiao B, et al. Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS One. 2011;6(7):e22659.
   PubMed Web of Science ®Google Scholar
• Pavón EJ, García-Rodríguez S, Zumaquero E, et al. Increased expression and phosphorylation of the two S100A9 isoforms in mononuclear cells from patients with systemic lupus erythematosus: a proteomic signature for circulating low-density granulocytes. J Proteomics. 2012;75(6):1778–1791.
   PubMed Web of Science ®Google Scholar
• Lood C, Stenström M, Tydén H, et al. Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res Ther. 2011;13(2):R60.
   PubMed Web of Science ®Google Scholar
• Ferreira TAR, De Andrade HM, De Pádua PM, et al. Identification of potential biomarkers for systemic lupus erythematosus diagnosis using two-dimensional differential gel electrophoresis (2D-DIGE) and mass spectrometry. Autoimmunity. 2017;50(4):247–256.
   PubMed Web of Science ®Google Scholar
• Nicolaou O, Kousios A, Hadjisavvas A, et al. Biomarkers of systemic lupus erythematosus identified using mass spectrometry‐based proteomics: a systematic review. J Cell Mol Med. 2017;21(5):993–1012.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Lin ZT, Wang H, et al. Protein arrays I: antibody arrays. Methods Mol Biol. 2017;1654:261–269.
   PubMedGoogle Scholar
• Yuan Y, Wang H, Lin ZT, et al. Protein arrays II: antigen arrays. Methods Mol Biol. 2017;1654:271–277.
   PubMedGoogle Scholar
• Yuan Y, Hong X, Lin ZT, et al. Protein arrays III: reverse-phase protein arrays. Methods Mol Biol. 2017;1654:279–289.
   PubMedGoogle Scholar
• Hinchliffe TE, Lin ZT, Wu T. Protein arrays for biomarker discovery in lupus. Proteomics Clin Appl. 2016 Jun;10(6):625–634.
   PubMed Web of Science ®Google Scholar
• Wu T, Xie C, Bhaskarabhatla M, et al. Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheumatol. 2007;56(3):949–959.
   Google Scholar
• Qin M, Guo Y, Jiang L, et al. Elevated levels of serum sCXCL16 in systemic lupus erythematosus; potential involvement in cutaneous and renal manifestations. Clin Rheumatol. 2014;33(11):1595–1601.
   PubMed Web of Science ®Google Scholar
• Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3(12):e491.
   PubMed Web of Science ®Google Scholar
• Zhen QL, Xie C, Wu T, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest. 2005;115(12):3428–3439.
   PubMed Web of Science ®Google Scholar
• Price JV, Haddon DJ, Kemmer D, et al. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J Clin Invest. 2013;123(12):5135.
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285(5425):260–263.
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–1756.
   PubMed Web of Science ®Google Scholar
• Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheumatol. 2003;48(11):3253–3265.
   PubMed Web of Science ®Google Scholar
• Cancro MP, D’cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066.
   PubMed Web of Science ®Google Scholar
• Chugh PK, Kalra BS. Belimumab: targeted therapy for lupus. Int J Rheum Dis. 2013;16(1):4–13.
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Huang W, Wang T, et al. Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging study. Arthritis Rheumatol. 2010;62(1):201–210.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Ginzler EM, Wallace DJ, et al. Long‐term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2012;64(10):3364–3373.
   PubMed Web of Science ®Google Scholar
• Wei F, Chang Y, Wei W. The role of BAFF in the progression of rheumatoid arthritis. Cytokine. 2015;76(2):537–544.
   PubMed Web of Science ®Google Scholar
• Pontarini E, Fabris M, Quartuccio L, et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren’s syndrome. Rheumatology. 2015;54(8):1429–1434.
   PubMed Web of Science ®Google Scholar
• Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20(16):1981.
   PubMed Web of Science ®Google Scholar
• Johnson SA, Hunter T. Kinomics: methods for deciphering the kinome. Nat Methods. 2005;2(1):17.
   PubMed Web of Science ®Google Scholar
• Kim M, Shin DS, Kim J, et al. Substrate screening of protein kinases: detection methods and combinatorial peptide libraries. Pept Sci. 2010;94(6):753–762.
   Google Scholar
• Taher TE, Parikh K, Flores‐Borja F, et al. Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheumatol. 2010;62(8):2412–2423.
   PubMedGoogle Scholar
• Winkler DG, Faia KL, DiNitto JP, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364–1374.
   PubMed Web of Science ®Google Scholar
• Barber DF, Bartolomé A, Hernandez C, et al. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med. 2005;11(9):933.
   PubMed Web of Science ®Google Scholar
• Wu T, Qin X, Kurepa Z, et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Investig. 2007;117(8):2186.
   PubMed Web of Science ®Google Scholar
• Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2006;54(9):2983–2988.
   PubMed Web of Science ®Google Scholar
• Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016;12(3):169.
   PubMed Web of Science ®Google Scholar
• Toro-Domínguez D, Carmona-Sáez P, Alarcón-Riquelme ME. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis. Arthritis Res Ther. 2017;19(1):54.
   PubMedGoogle Scholar
• Vanhaesebroeck B, Ali K, Bilancio A, et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30(4):194–204.
   PubMed Web of Science ®Google Scholar
• Suárez-Fueyo A, Rojas JM, Cariaga AE, et al. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. J Immunol. 2014;193(2):544–554.
   PubMed Web of Science ®Google Scholar
• Wu T, Ye Y, Min SY, et al. Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid. Arthritis Rheumatol. 2014;66(11):3129–3139.
   PubMed Web of Science ®Google Scholar
• Bardwell PD, Gu J, McCarthy D, et al. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol. 2009;182(12):7482–7489.
   PubMed Web of Science ®Google Scholar
• Wu L, Qin Y, Xia S, et al. Identification of cyclin‐dependent kinase 1 as a novel regulator of type I interferon signaling in systemic lupus erythematosus. Arthritis Rheum. 2016;68(5):1222–1232.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hayakawa K, Fujishiro M, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41.
   PubMedGoogle Scholar
• Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010;6(12):683.
   PubMed Web of Science ®Google Scholar
• Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet. 2008;40(9):1059.
   PubMed Web of Science ®Google Scholar
• Han J-W, Zheng H-F, Cui Y, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1234.
   PubMed Web of Science ®Google Scholar
• Hahne M, Kataoka T, Schröter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188(6):1185–1190.
   PubMed Web of Science ®Google Scholar
• Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res. 2011;317(9):1270–1277.
   PubMed Web of Science ®Google Scholar
• Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64(7):1065–1067.
   PubMed Web of Science ®Google Scholar
• Koyama T, Tsukamoto H, Masumoto K, et al. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology. 2003;42(8):980–985.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–2015.
   Web of Science ®Google Scholar
• Lu J, Kwan BCH, Lai FMM, et al. Gene expression of TWEAK/Fn14 and IP‐10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology. 2011;16(4):426–432.
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Wisniacki N, Burkly LC, et al. Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun. 2012;39(3):130–142.
   PubMed Web of Science ®Google Scholar
• Brightbill HD, Suto E, Blaquiere N, et al. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat Commun. 2018;9(1):179.
   PubMedGoogle Scholar
• Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose‐escalation trial of rituximab. Arthritis Rheumatol. 2004;50(8):2580–2589.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol. 2004;16(3):180–185.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatology. 2007;17(3):191–197.
   PubMedGoogle Scholar
• Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748.
   PubMed Web of Science ®Google Scholar
• Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74(7):1474–1478.
   Web of Science ®Google Scholar
• Stirzaker R, Biswas P, Gupta S, et al. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus. 2012;21(6):656–661.
   PubMed Web of Science ®Google Scholar
• O’gorman WE, Hsieh EW, Savig ES, et al. Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus. J Allergy Clin Immunol. 2015;136(5):1326–1336.
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Koyama S, Nakagawa A, et al. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe. 2008;3(6):352–363.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.
   PubMed Web of Science ®Google Scholar
• Netea MG, Wijmenga C, O’neill LA. Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol. 2012;13(6):535.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Tus K, Q-Z L, et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci. 2006;103(26):9970–9975.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Chan JH, et al. Treatment of lupus‐prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007;37(12):3582–3586.
   PubMed Web of Science ®Google Scholar
• Capolunghi F, Rosado MM, Cascioli S, et al. Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology. 2010;49(12):2281–2289.
   PubMed Web of Science ®Google Scholar
• Lacerte P, Brunet A, Egarnes B, et al. Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists. Arthritis Res Ther. 2016;18(1):10.
   PubMedGoogle Scholar
• Kim S, Chen Z, Essani AB, et al. Identification of a novel Toll‐like Receptor 7 endogenous ligand in rheumatoid arthritis synovial fluid that can provoke arthritic joint inflammation. Arthritis Rheum. 2016;68(5):1099–1110.
   Web of Science ®Google Scholar
• Crow MK. Interferon‐α: A new target for therapy in systemic lupus erythematosus? Arthritis Rheumatol. 2003;48(9):2396–2401.
   PubMedGoogle Scholar
• Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–723.
   PubMed Web of Science ®Google Scholar
• Mathian A, Amoura Z, Adam E, et al. Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus. Ann Rheum Dis. 2011;70(6):1138–1143.
   Web of Science ®Google Scholar
• Zagury D, Le Buanec H, Mathian A, et al. IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci. 2009;106(13):5294–5299.
   PubMed Web of Science ®Google Scholar
• Furie R, Merrill J, Werth V, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheumatol. 2015;67:3865–3868.
   Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916.
   Web of Science ®Google Scholar
• Salvi V, Bosisio D, Mitola S, et al. Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. Immunobiology. 2010;215(9):756–761.
   PubMed Web of Science ®Google Scholar
• Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus—focus on targeting interferon-alpha. Clin Immunology. 2012;143(3):210–221.
   PubMed Web of Science ®Google Scholar
• Comte D, Karampetsou MP, Tsokos GC. T cells as a therapeutic target in SLE. Lupus. 2015;24(4–5):351–363.
   PubMed Web of Science ®Google Scholar
• Edwards LJ, Mizui M, Kyttaris V. Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin Immunol. 2015;158(2):221–230.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017;4(1):e000239.
   PubMed Web of Science ®Google Scholar
• López P, Rodríguez-Carrio J, Caminal-Montero L, et al. A pathogenic IFNα, BLyS and IL-17 axis in systemic lupus erythematosus patients. Sci Rep. 2016;6:20651.
   Web of Science ®Google Scholar
• Shah K, Lee -W-W, Lee S-H, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(2):R53.
   PubMed Web of Science ®Google Scholar
• Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(6):R204.
   PubMed Web of Science ®Google Scholar
• Liao W, Li M, Wu H, et al. Down-regulation of MBD4 contributes to hypomethylation and overexpression of CD70 in CD4+ T cells in systemic lupus erythematosus. Clin Epigenetics. 2017;9(1):104.
   PubMedGoogle Scholar
• Wu X-N, Ye Y-X, Niu J-W, et al. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med. 2014;6(246):246ra99–46ra99.
   PubMed Web of Science ®Google Scholar
• Cheung RK, Utz PJ. Screening: cyTOF—the next generation of cell detection. Nat Rev Rheumatol. 2011;7(9):502–503.
   PubMed Web of Science ®Google Scholar
• Roederer M. Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry Part A. 2001;45(3):194–205.
   Google Scholar
• Bendall SC, Simonds EF, Qiu P, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332(6030):687–696.
   PubMed Web of Science ®Google Scholar
• Nowicka M, Krieg C, Weber LM, et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Research. 2017;6:748.
   Google Scholar
• Yao Y, Liu R, Shin MS, et al. CyTOF supports efficient detection of immune cell subsets from small samples. J Immunol Methods. 2014;415:1–5.
   PubMed Web of Science ®Google Scholar
• Parodis I, Ramsköld D, Tadepally L, et al. 104 A mass cytometry (CYTOF) approach to study B cell alterations during baff blockade treatment with belimumab in systemic lupus erythematosus. Arch Dis Child. 2017;4(Suppl 1):A44–A45.
   Google Scholar
• Leipold MD. Another step on the path to mass cytometry standardization. Cytometry Part A. 2015;87(5):380–382.
   PubMedGoogle Scholar
• Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PloS One. 2010;5(12):e15004.
   PubMed Web of Science ®Google Scholar
• Lin ZT, Gu J, Li CH, et al. A nanoparticle‐decorated biomolecule‐responsive polymer enables robust signaling cascade for biosensing. Adv Mater. 2017 Aug;29(31):1702090.
   Web of Science ®Google Scholar
• Gold L, Walker JJ, Wilcox SK, et al. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol. 2012;29(5):543–549.
   PubMed Web of Science ®Google Scholar
• Ostroff RM, Bigbee WL, Franklin W, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PloS One. 2010;5(12):e15003.
   PubMedGoogle Scholar
• Björk P, Björk A, Vogl T, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009;7(4):e1000097.
   Web of Science ®Google Scholar
• Bengtsson AA, Sturfelt G, Lood C, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR‐215757), a new quinoline‐3‐carboxamide derivative: studies in lupus‐prone mice and a multicenter, randomized, double‐blind, placebo‐controlled, repeat‐dose, dose‐ranging study in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2012;64(5):1579–1588.
   PubMed Web of Science ®Google Scholar
• Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2012;64(7):2328–2337.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323–331.
   Web of Science ®Google Scholar
• Merrill J, Van Vollenhoven R, Buyon J, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):332–340.
   Web of Science ®Google Scholar
• Tran NL, Schneider P, Santiago‐Raber ML. TACI‐dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus. Eur J Immunol. 2017;47(4):713–723.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol. 2007;179(11):7949–7958.
   PubMed Web of Science ®Google Scholar
• Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol. 1996;157(7):3159–3164.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trial. Arthritis Rheumatol. 2002;46(12):3251–3258.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheumatol. 2003;48(3):719–727.
   PubMed Web of Science ®Google Scholar
• Mizui M, Koga T, Lieberman LA, et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4− CD8− IL-17–producing T cells. J Immunol. 2014;193(5):2168–2177.
   PubMed Web of Science ®Google Scholar
• Lai Z-W, Borsuk R, Shadakshari A, et al. mTOR activation triggers proinflammatory expansion of IL-4-producing and necrosis-prone double-negative T cells, precedes flares, and serves as target for treatment in patients with systemic lupus erythematosus. Arthritis Res Ther. 2014;16(1):A25.
   Google Scholar
• Gu Z, Tan W, Ji J, et al. Rapamycin reverses the senescent phenotype and improves immuno-regulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway. Aging (Albany NY). 2016;8(5):1102–1104
   PubMedGoogle Scholar
• Anderson NL, Anderson NG. The human plasma proteome history, character, and diagnostic prospects. Molecular & Cellular Proteomics. 2002;1(11):845–867.
   PubMed Web of Science ®Google Scholar